



Leishmanivirus genetic diversity is not related to leishmaniasis treatment failure

Marine Ginouvès, Pierre Couppié, Stéphane Simon, Eliane Bourreau, Stéphanie Rogier, Paul Brousse, Philippe Travers, Vincent Pommier de Santi, Magalie Pierre Demar, Sebastien Briolant, et al.

► To cite this version:

Marine Ginouvès, Pierre Couppié, Stéphane Simon, Eliane Bourreau, Stéphanie Rogier, et al.. Leishmanivirus genetic diversity is not related to leishmaniasis treatment failure. *Clinical Microbiology and Infection*, 2020, pp.S1198-743X(20)30265-2. 10.1016/j.cmi.2020.04.037 . hal-02569704

HAL Id: hal-02569704

<https://amu.hal.science/hal-02569704>

Submitted on 9 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Title: *Leishmaniovirus* genetic diversity is not related to leishmaniasis treatment failure.

Running title: LRV1 genetic diversity

Authors: Marine Ginouvès, Pierre Couppié, Stéphane Simon, Eliane Bourreau, Stéphanie Rogier, Paul Brousse, Philippe Travers, Vincent Pommier de Santi, Magalie Demar, Sébastien Briolant, Ghislaine Prévot

Ginouvès Marine and Simon Stéphane, Ecosystemes Amazoniens et Pathologie Tropicale – EA 3593 – Labex CEBA – Medicine department, University of French Guiana, Cayenne, French Guiana, Laboratoire Associé – Centre National de Référence Leishmania, Laboratory of Parasitology and Mycology, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana, E-mails :

marine.ginouves@univ-guyane.fr, stephane.simon@guyane.univ-ag.fr,

Couppié Pierre, Ecosystemes Amazoniens et Pathologie Tropicale – EA 3593 – Labex CEBA – Medicine department, University of French Guiana, Cayenne, French Guiana and Guianan Institute of Tropical Dermatology, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana, E-mail : pierre.couppie@ch-cayenne.fr,

Bourreau Eliane, Immunology Laboratory of Leishmaniasis, Pasteur Institute of French Guiana, Cayenne, French Guiana, E-mail : ebourreau@pasteur-cayenne.fr,

Rogier Stéphanie, Centre d'Investigation Clinique Epidémiologie Clinique Antilles Guyane CIC EC 1424, Cayenne General Hospital, Cayenne, French Guiana, stephanie.rogier@ch-cayenne.fr,

Brousse Paul and Travers Philippe, Centres Délocalisés de Prévention et de Soins (C.D.P.S.), Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana, paul.brousse@ch-cayenne.fr and travers.philippe@gmail.com,

22 Pommier de Santi Vincent, French Armed Forces Center for Epidemiology and Public Health,
 23 Marseille, France. Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France. IHU-
 24 Méditerranée Infection, Marseille, France: v.pommierdesanti@gmail.com

 25 Briolant Sébastien, French Armed Forces Center for Epidemiology and Public Health, Marseille,
 26 France. Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France. IHU-Méditerranée
 27 Infection, Marseille, France : sbriolant@wanadoo.fr

 28 Demar Magalie, Ecosystemes Amazoniens et Pathologie Tropicale – EA 3593 – Labex CEBA –
 29 Medicine department, University of French Guiana, Cayenne, French Guiana, Laboratoire Associé –
 30 Centre National de Référence Leishmania, Laboratory of Parasitology and Mycology, Centre
 31 Hospitalier Andrée Rosemon, Cayenne, French Guiana and Laboratory of Parasitology and Mycology,
 32 Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana, E-mail : magalie.demar@ch-
 33 cayenne.fr,

 34 Prévot Ghislaine, Ecosystemes Amazoniens et Pathologie Tropicale – EA 3593 – Labex CEBA –
 35 Medicine department, University of French Guiana, Cayenne, French Guiana, E-mail :
 36 fac.prevot@gmail.com

 37

 38 **Abstract**

 39 *Objectives:* The outcome of American tegumentary leishmaniasis (ATL) may depend on the presence
 40 of the *Leishmania* RNA virus (LRV). This virus may be involved in treatment failure. We aimed to
 41 determine whether genetic clusters of LRV1 are involved in this therapeutic outcome.

 42 *Methods:* The presence of LRV1 was assessed in 129 *L. guyanensis* isolates from patients treated with
 43 pentamidine in French Guiana. Among the 115 (89%) isolates found to carry LRV1, 96 were
 44 successfully genotyped. Patient clinical data were linked to the LRV data.

Results: The rate of treatment failure for LRV1-positive isolates was 37% (15/41) versus 40% (2/5) among LRV1-negative isolates ($p = 0.88$). Concerning LRV1 genotypes, two predominant LRV1 groups emerged, groups A (23% (22/96)) and B (70% (67/96)). The treatment failure rate was 37% (3/8) for group A and 45% (9/20) for group B ($p = 0.31$).

Conclusion: Neither the presence or genotype of LRV1 in patients with *L. guyanensis* seemed to correlate with pentamidine treatment failure.

Key words: *Leishmania guyanensis*, LRV1, genotype, treatment failure, pentamidine

Introduction

Leishmaniasis are infectious diseases caused by *Leishmania* (*Trypanosomatidae*) parasites, which are transmitted through the bites of infected female sandflies. The disease is characterized by a wide range of clinical presentations, from asymptomatic to severe forms, depending on the *Leishmania* species. American tegumentary leishmaniasis (ATL) is characterized by cutaneous lesions and can result in self-healing or spread of the lesions. Localized cutaneous leishmaniasis (LCL) is defined as a skin lesion localized at the point of the vector bite. In some patients, parasites spread throughout the body, causing cutaneous diffuse leishmaniasis (CDL). Mucocutaneous leishmaniasis (MCL) occurs when the parasite spreads from a cutaneous lesion to nasopharyngeal areas of the face, leading to destructive metastatic secondary lesions.

The presence of the *Leishmania* RNA virus (LRV) may be a factor associated with the development of mucosal leishmaniasis (1–4). LRV is a non-enveloped double-stranded RNA virus belonging to the *Totiviridae* family. This virus, initially believed to be exclusively hosted by *Leishmania* parasites, was recently found in another *Trypanosomatidae* of the genus *Blechnomonas* (5). LRV has been described in New- and Old-World strains of *Leishmania*, named LRV1 and LRV2, respectively, and has been

particularly studied for the *Viannia* subgenus. Six phylogenetic groups of LRV1 can be distinguished in this subgenus, from A to F, with two predominant clusters, A and B. Clusters A to E are comprised of *L. guyanensis* parasites and cluster F includes two isolates from *L. braziliensis* (6).

LRV1 appears to play a role in disease progression by directing it towards the severe MCL (1). Indeed, the presence of this virus, carried by *L. guyanensis* parasites, appears to modulate the host immune response in a murine model, leading to a higher susceptibility to the infection, an increase in parasite burden, swelling of the lesions, and metastases. The virus appears to activate host immune receptors, such as Toll-Like Receptor-3 (TLR-3), inducing pro-inflammatory cytokine synthesis and leading to an excessive immune response. The exaggerated immune response directed initially against the parasites simultaneously affects host tissues, leading to their substantial degradation (1). This exacerbation may be amplified by association of the virus with parasitic exosomes (7) but can be prevented by immunization with LRV capsid proteins in mice (8). In humans, LRV1 appears to be a predictive factor of first-line treatment failure and symptomatic relapses (9). However, a recent study has suggested otherwise (10). Here, we aimed to determine whether the presence of LRV1 or one of its genotypes correlates with treatment failure.

Materials and methods

Patients

The study, conducted in French Guiana, included patients with a diagnosis of tegumentary leishmaniasis due to *L. guyanensis* between February 2012 and May 2016.

The diagnosis consisted of a biopsy of the interior of the lesions of the patients, followed by incubation of the biopsy in RPMI-1640 (Gibco®), containing L-glutamine, 20 mM HEPES, and phenol red, supplemented with 20% heat-inactivated fetal calf serum (FCS) (Gibco), 50 IU/mL penicillin (Invitrogen®), 0.05 mg/mL streptomycin (Invitrogen), and nonessential amino acids (Gibco), at 26°C to allow development of the parasite. Part of the culture was used for the routine diagnosis of *Leishmania* species performed by the Cayenne hospital by PCR-RFLP (11) and the other kindly

94 supplied by the Cayenne hospital for LRV1 detection and analysis. Patients diagnosed as positive for
95 *L. guyanensis* but with an unsuccessful culture were not included in the study.

96 In total, 332 cultures were available. The isolates were associated with patient data. Patients without
97 therapeutic outcome data after the first round of treatment and those under 18 years of age were
98 excluded from the study. Finally, 129 patients were included. A sensitivity analysis was carried out to
99 ensure that patient exclusion did not affect the study results (data not shown).

100 **LRV RNA extraction**

101 Upon reaching stationary phase, fresh *Leishmania* cultures were counted under a microscope. Pellets
102 of 1.10^7 parasites were prepared by a 5-min centrifugation at 587 x g and elimination of the
103 supernatant. Cells were preserved at -25°C until use.

104 Total RNA was extracted from *Leishmania* promastigotes using the RNeasy mini kit® according to the
105 manufacturer's recommendations (except for centrifugations of 15 s, which were extended to 30 s
106 because of the characteristics of the centrifuge). The RNA was stored at -80°C until use.

107 **LRV Reverse transcription**

108 RNA reverse transcription was performed using SuperScript™ II Reverse Transcriptase (Invitrogen)
109 with random hexamers (Invitrogen), according to the manufacturer's recommendations.

110 **LRV1 detection by PCR**

111 LRV1 was detected by amplification of a 124-bp fragment by PCR with the LRV1 forward primer,
112 LRV1-F1: 5'- CTGACTGGACGGGGGTAAT-3' and the LRV1 reverse primer, LRV1-R1: 5'-
113 CAAAACACTCCCTTACGC-3', at a final concentration of 0.2 μM (12). The 25-μL reaction mixture
114 included 1X PCR master mix (BiotechRabbit™), 0.2 μM of each primer, and 2 μL cDNA. A denaturation
115 step at 94°C for 2 min was followed by 40 cycles at 94°C for 30 s, 54°C for 30 s, and 72°C for 1 min.
116 The PCR was completed by a final elongation step at 72°C for 5 min. PCR products were separated on
117 a 2% agarose gel with Midori Green Advance® to verify the presence of amplification products of the

expected size. The reference strain of *L. guyanensis* (MHOM/GF/97/LBC6) was used as a positive control and water as a negative control in each PCR experiment.

LRV genotyping

PCR

Positive LRV1 samples were genotyped using the forward primer LRV1s 5'-ATTCGCTAGCTGTYBGGATGGTAGYGTAC-3' and the reverse primer LRV2as 5'-CATAGCCAAAACGTTCACAWARTGTYGRGTGT-3' (6), amplifying a 779 bp product. These primers target the ORF1 and ORF2 sequences that encompass the sequence amplified by the LRV1-F1/LRV1-R1 primers used for LRV1 detection. The 50- μ L reaction mixture included 1X AmpliTaqGold master mix (Applied Biosystem™), 0.2 μ M of each primer, and 5 μ L cDNA. A denaturation step at 94°C for 5 min was followed by 35 cycles at 94°C for 30 s, 62°C for 30 s, and 72°C for 1 min. The PCR was completed by a final elongation step at 72°C for 5 min.

Fragments not amplified by the LRV1s/LRV2as primers were amplified using another primer pair proposed by Cantanhêde et. al (13), surrounding the sequence amplified by the LRV1s/LRV2as primers. These primers were LRV1 F orf1 5'-ATGCCTAAGAGTTTGGATTCG-3' and LRV R orf2 5'-AATCAATTTTCCCAGTCATGC-3', amplifying an 850 bp sequence.

The 50- μ L reaction mixture included 1X AmpliTaqGold master mix (Applied Biosystem™), 0.4 μ M of each primer, and 5 μ L of cDNA. A denaturation step at 94°C for 2 min was followed by 40 cycles at 94°C for 30 s, 56°C for 45 s, and 72°C for 30 s. The PCR was completed by a final elongation step at 72°C for 3 min.

PCR products were separated on a 2% agarose gel containing Midori Green Advance® to verify the presence of amplification products of the expected size.

Sequencing

Sample purification and sequencing were performed from 40 µL of PCR product by the sequencing platform of l'Hôpital Cochin (Eurofins France) with the corresponding primers used for fragment amplification. Both strands of each sample were sequenced and the results delivered by the subcontractor, Eurofins.

Sequence analysis

Sequence complementarity (forward and reverse) obtained for each sample was tested using BioEdit software (version 7.0.5.3) (14) to confirm the sequencing. The consensus sequence resulting from two strictly identical opposed sequences was selected for the genetic analysis. We also included the 24 sequences from the study of Tirera et al. (6), 11 of which corresponded to the isolates used in our study. All LRV sequences were aligned with MEGA 7 software (15) using the MUSCLE program. Some alignment corrections were made manually. A phylogenetic tree was constructed using SeaView software (16), based on maximum likelihood phylogenies (PhyML) and the K80 model (default settings).

Clinical data

Clinical data were retrospectively sought for the 129 *Leishmania* samples in the various services of the hospital or health centers spread throughout the territory. Collected data included age, gender, suspected place of infection, number of lesions, lesion size, nodules, papules, satellite papules, lymphangitis, adenopathy, and treatment failure.

Data analysis

R software (version 3.2.0) was used for data analysis. Univariate and multivariate variables were analyzed by logistic regression. Variables included in the statistical analysis were the presence of LRV1, LRV1 genotype, age, gender, suspected place of infection, time between infection and treatment, time between two rounds of pentamidine, number of lesions, lesion size, lymphangitis, adenopathy, nodule, papule, satellite papules, and treatment failure after one or two courses of pentamidine.

LRV1 genotypes were separated into six groups, from A to F. Only groups A and B were analyzed. The other groups were excluded due to their small size. Age was divided into two groups: from 18 to 35 years and > 35. The suspected locations of infection were grouped into two areas: littoral (Iracoubo, Macouria, Sinnamary, Kourou, Matoury, Cayenne, Rémire-Montjoly) and inland (Régina, Saül, Saint-Elie, Roura, Montsinéry-Tonnegrande, Saint-Georges, Camopi, Trois-Sauts, Saint-Laurent du Maroni, Apatou, Grand-Santi, Papaïchton and Maripasoula). Patients who consulted in French Guiana but were infected in neighboring countries were included in the study. Thus, Suriname and Brazil were also included in the inland group. Lesion number was divided into two groups, the first consisting of patients with one lesion and the second, those with more than one lesion. Lesion size was also divided into two groups, the first consisting of patients with lesions ≤ 2 cm and the second, those > 2 cm.

Patients included in the study were treated by intramuscular administration of 7 mg/kg pentamidine, divided between two injections given in a single day at different body sites. In the absence of healing of the lesion at least one month after the first treatment (treatment 1), a second dose of pentamidine was administered by the intramuscular route. Treatment failure was considered when patients presented a persistent lesion at least one month after the second course of treatment (treatment 2). Patients showing treatment failure were hospitalized for meglumine antimoniate (Glucantime®) treatment. The influence of LRV on therapeutic failure was determined after the first and second round of treatment.

Ethical approval

Access to these data has been authorized by the Comité de Protection des Personnes (CPP) SUD-EST II, n° ID-RCB: 2017-A00173-50. A declaration was also made to the Commission Nationale de l'Informatique et des Libertés (CNIL), n° peV2056324t.

Results

LRV and clinical outcomes

The study included 129 *L. guyanensis* isolates, for which the presence of LRV was sought. The results were associated with the available data on the various clinical features of the patients to identify the involvement of this virus in the pathophysiology of the disease (Table 1, see web-only Supplementary Table S1). Thus, among the 115 (89%) *Leishmania* samples harboring LRV1, 63% (73/115) resulted in the patients being unresponsive to the first round of pentamidine versus 57% (8/14) for the LRV-negative patients. In the second round of treatment, 37% of the 41 positive LRV1 isolates (15/41) were associated with treatment failure versus 40% (2/5) for the LRV-negative patients. There was no significant association between treatment failure and the presence of LRV1 ($p = 0.88$).

Statistical analysis of the other variables showed that LRV1 did not affect the development of adenopathy, lymphangitis, papules, satellite papules, nodules, or the size or number of lesions. Neither age nor gender influenced the development of LRV1.

Geographical analysis showed a much stronger presence of LRV1 inlands than at the coastline (OR = 9.8, $p = 0.0008$).

LRV genotyping

LRV1 amplification by PCR using the various primers, as part of the sequencing, is shown in Figure 1. Among the 115 LRV1 isolates, 96 were successfully sequenced and used to construct a phylogenetic tree. Thirteen other sequences, from the study of Tirera et al., were also included (6). The phylogenetic tree (see web-only Supplementary Figure S1) highlighted five groups, from A to E. The groups A and B were predominant, accounting for 22 (23%) and 67 (70%) of the LRV1 isolates, respectively. Groups D and E accounted for 1 (1%) and 6 (6%) LRV1 isolates. No LRV1 isolates used in this study belonged to groups C or F.

LRV genotypes related to clinical outcome

Among the 96 genotyped LRV isolates, 89 were distributed within clusters A and B. In group A, 59% (13/22) of the LRV isolates were associated with the unresponsiveness of patients to the first round of pentamidine and 63% (42/67) in group B. In the second round of treatment, 37% (3/8) of the LRV

isolates of group A were associated with treatment failure versus 45% (9/20) in group B. None of the LRV1 groups seemed to be associated with treatment failure ($p = 0.31$) or to the development of adenopathy, lymphangitis, papules, satellite papules, nodules, large lesions, or the number of lesions. The LRV1 groups did not appear to be associated with age, gender, or geographic area (Table 2, see web-only Supplementary Table S1).

Discussion

The presence of LRV1 has been shown to be a risk factor for therapeutic failure (9,17). In the present study, we found no correlation between the presence of LRV1 or its genotypes in *L. guyanensis* parasites and treatment failure, either after the first or second course of treatment of pentamidine. The main difference, and limitation, of this study relative to the others was that this study was retrospective and included patients with non-standardized clinical monitoring. Our results contrast with those of Bourreau et al. and Adaui et al. (9,17), but are in accordance with those of Christen et al. (10). A prominent difference between our study, that of Bourreau et al. (9), and that of Christen et al. (10) was the diagnostic methodology used. Bourreau et al. performed LRV1 detection directly on biopsies, whereas we detected LRV1 from cultures. Christen et al. used both methodologies, biopsies or cultures, depending on the case (personal communication). However, according to Bourreau et al., LRV1 prevalence was higher in parasite cultures (87%) than in biopsies (58%). Such a higher prevalence of LRV1 in cultures was observed in our study and that of Christen et al., 89% and 85%, respectively. Indeed, low amounts of LRV1 in a biopsy may render the virus undetectable by molecular biology, whereas it may be detected in culture. This may lead to bias, especially since, according to Ives et al., the magnitude of the immune response induced by LRV1 should depend on its amount (1). This could explain the absence of a correlation between the presence of LRV1 and treatment failure in the present study. Nevertheless, Adaui et al. found a correlation between the presence of LRV1 in cultivated *L. braziliensis* isolates and treatment failure (17). However, Bourreau et al. reported that treatment failure did not correlate with the LRV1 load per parasite (9) and another study reported that the LRV1 burden (genome equivalent) did not correlate with the state of

the lesion (active lesion, lesion in the process of scarring, or scar), as the amount of LRV1 was highly variable, regardless of the state of the lesion (18). Another difference observed between these various studies was that Adaui et al. and Bourreau et al. included relapsing patients, which was not the case in our study or that of Christen et al. (9,10,17). Pereira et al. also reported that LRV1 was detected in patients with disease reactivation (19). Thus, LRV1 may be only responsible for relapses. Future studies to investigate the association of LRV1 genotypes with disease should therefore only be carried out on samples from relapsing patients.

Acknowledgment:

We thank all trainees who participated in this project at the level of experimental work (Claudiane FLORAT, Yasmine AUGUSTE, Ruthly JEAN-BAPTISTE, Keïta BAGADI, Kévin JOSEPH). We also thank all CHC staff (Audrey Ambouille, Géraldine Gangasing, Philippe Travers, Basma Guarmit, Céline Michaud) and health centers staff (Maripasoula: Christelle Maabo, Wilmina Alfred, Melaine Boce and their colleagues, Papaichton: Naïka Amayota and colleagues, in Cacao: Malika Miquel and colleagues, in Saint Georges: Eric Crougneau and colleagues, in Apatou : Pauline Alifons and colleagues, in Saül : Séverine and colleagues, in Trois sauts : Benoit Quentin, Laure Gerold and colleagues) who helped us to carry out this project. We thank Antoine Adenis for his help in the sensitivity study. We thank reviewers and editor for their advice.

Conflict of interest

The authors declare that they have no competing interests.

Financial support

This work was supported by the University of French Guiana and the Ministère Français de l'Enseignement Supérieur et de la Recherche Scientifique.

This work has benefited from an "Investissement d'Avenir" grant managed by Agence Nationale de la Recherche (CEBA, ref. ANR-10-LABX-25-01).

Corresponding author:

marine.ginouves@univ-guyane.fr, University of French Guiana, DFR santé, Laboratoire EPaT, Campus Saint Denis, Avenue d'Estrées, 97300 Cayenne, +594 694 99 04 82

Authors' contributions

The conception and design of the study: GP, PC and MG. Acquisition of data: all the authors. Analysis and interpretation of data: SB, GP, MG. Drafting the article: GP, PC, SB, MG. Revising it critically for important intellectual content: all authors. Final approval of the version to be submitted: all authors.

References

1. Ives A, Ronet C, Prevel F, Ruzzante G, Fuertes-Marraco S, Schutz F, et al. Leishmania RNA Virus Controls the Severity of Mucocutaneous Leishmaniasis. *Science*. 2011 Feb 11;331(6018):775–8.
2. Cantanhêde LM, da Silva Júnior CF, Ito MM, Felipin KP, Nicolette R, Salcedo JMV, et al. Further Evidence of an Association between the Presence of Leishmania RNA Virus 1 and the Mucosal Manifestations in Tegumentary Leishmaniasis Patients. Bates PA, editor. *PLOS Neglected Tropical Diseases*. 2015 Sep 15;9(9):e0004079.
3. Ito MM, Catanhêde LM, Katsuragawa TH, da Silva Junior CF, Camargo LMA, Mattos R de G, et al. Correlation between presence of Leishmania RNA virus 1 and clinical characteristics of nasal mucosal leishmaniosis. *Brazilian Journal of Otorhinolaryngology*. 2015 Sep;81(5):533–40.
4. de Carvalho RVH, Lima-Junior DS, da Silva MVG, Dilucca M, Rodrigues TS, Horta CV, et al. Leishmania RNA virus exacerbates Leishmaniasis by subverting innate immunity via TLR3-mediated NLRP3 inflammasome inhibition. *Nat Commun*. 2019 Dec;10(1):5273.

- 290 5. Grybchuk D, Akopyants NS, Kostygov AY, Konovalovas A, Lye L-F, Dobson DE, et al. Viral
291 discovery and diversity in trypanosomatid protozoa with a focus on relatives of the human
292 parasite *Leishmania*. Proceedings of the National Academy of Sciences. 2018 Jan
293 16;115(3):E506–15.
- 294 6. Tirera S, Ginouves M, Donato D, Caballero IS, Bouchier C, Lavergne A, et al. Unraveling the
295 genetic diversity and phylogeny of Leishmania RNA virus 1 strains of infected Leishmania
296 isolates circulating in French Guiana. Tibayrenc M, editor. PLOS Neglected Tropical Diseases.
297 2017 Jul 17;11(7):e0005764.
- 298 7. Atayde VD, da Silva Lira Filho A, Chaparro V, Zimmermann A, Martel C, Jaramillo M, et al.
299 Exploitation of the Leishmania exosomal pathway by Leishmania RNA virus 1. Nature
300 Microbiology [Internet]. 2019 Jan 28 [cited 2019 Feb 4]; Available from:
301 <http://www.nature.com/articles/s41564-018-0352-y>
- 302 8. Castiglioni P, Hartley M-A, Rossi M, Prevel F, Desponds C, Utzschneider DT, et al. Exacerbated
303 leishmaniasis caused by a viral endosymbiont can be prevented by immunization with its viral
304 capsid. PLoS neglected tropical diseases. 2017;11(1):e0005240.
- 305 9. Bourreau E, Ginouves M, Prévot G, Hartley M-A, Gangneux J-P, Robert-Gangneux F, et al.
306 Presence of *Leishmania* RNA Virus 1 in *Leishmania guyanensis* Increases the Risk of First-Line
307 Treatment Failure and Symptomatic Relapse. Journal of Infectious Diseases. 2016 Jan
308 1;213(1):105–11.
- 309 10. Christen J-R, Bourreau E, Demar M, Lightburn E, Couppié P, Ginouvès M, et al. Use of the
310 intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous
311 leishmaniasis increases the risk of treatment failure. Travel Medicine and Infectious Disease
312 [Internet]. 2018 Mar [cited 2018 Apr 12]; Available from:
313 <http://linkinghub.elsevier.com/retrieve/pii/S1477893918300401>
- 314 11. Simon S, Veron V, Carme B. Leishmania spp. identification by polymerase chain reaction–
315 restriction fragment length polymorphism analysis and its applications in French Guiana.
316 Diagnostic Microbiology and Infectious Disease. 2010 Feb;66(2):175–80.
- 317 12. Ginouvès M, Simon S, Bourreau E, Lacoste V, Ronet C, Couppié P, et al. Prevalence and
318 Distribution of Leishmania RNA Virus 1 in Leishmania Parasites from French Guiana. The
319 American Journal of Tropical Medicine and Hygiene. 2016 Jan 6;94(1):102–6.
- 320 13. Cantanhêde LM, Fernandes FG, Ferreira GEM, Porrozzi R, Ferreira R de GM, Cupolillo E. New
321 insights into the genetic diversity of Leishmania RNA Virus 1 and its species-specific relationship
322 with Leishmania parasites. Clos J, editor. PLOS ONE. 2018 Jun 18;13(6):e0198727.
- 323 14. Hall T. Bioedit: A user-friendly biological sequence alignment editor and analysis program for
324 windows 95/98/NT. Nucleic acids symp ser. 1999;(41):95–8.
- 325 15. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0
326 for Bigger Datasets. Mol Biol Evol. 2016;33(7):1870–4.
- 327 16. Galtier N, Gouy M, Gautier C. SEAVIEW and PHYLO_WIN: two graphic tools for sequence
328 alignment and molecular phylogeny. Comput Appl Biosci. 1996 Dec;12(6):543–8.
- 329 17. Adaui V, Lye L-F, Akopyants NS, Zimic M, Llanos-Cuentas A, Garcia L, et al. Association of the
330 Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis

331 Caused by *Leishmania braziliensis* in Peru and Bolivia. Journal of Infectious Diseases. 2015 Jun
332 8;213(1):112–21.

333 18. Ogg MM, Carrion Jr R, BOTELHO ACDC, Mayrink W, Correa-Oliveira R, Patterson JL.
334 quantification of leishmanivirus RNA in clinical samples and its possible role in pathogenesis.
335 The American journal of tropical medicine and hygiene. 2003;69(3):309–313.

336 19. Pereira L de OR, Maretti-Mira AC, Rodrigues KM, Lima RB, Oliveira-Neto MP de, Cupolillo E, et
337 al. Severity of tegumentary leishmaniasis is not exclusively associated with Leishmania RNA
338 virus 1 infection in Brazil. Memórias do Instituto Oswaldo Cruz. 2013 Aug;108(5):665–7.

339

340




Figure 1 : LRV PCR with the different primers : LRV1-F1/LRV1-R1 [12] used for the LRV detection, LRV1s/LRV2as [6] and LRV1-F-orf1/LRV-R-orf2 [13] used for the LRV genotyping. LRVa corresponded to the non-amplified sample using LRV1s/LRV2as primers, but amplified using the LRV1-F-orf1/LRV-R-orf2 primers. LRVb corresponded to the non-amplified sample using LRV1s/LRV2as primers or LRV1-F-orf1/LRV-R-orf2 primers.

Table 1 : Statistical analysis of variables tested with LRV

				Univariate analysis	
		LRV-	LRV+	OR	p-value
Age	18-35 years hold	5	53	0,65	0,46
	> 35 years hold	9	62		
Gender	female	4	12	3,04	0,10
	male	8	73		
Time between two rounds of pentamidine	1 month	1	20	0,28	0,29
	> 1 month	3	17		
Time between infection and treatment	≤ 50 days	4	44	0,56	0,40
	> 50 days	6	37		
Treatment 1	cure	6	42	1,30	0,64
	failure	8	73		
Treatment 2	cure	3	26	0,87	0,88
	failure	2	15		
Suspected place of infection	Littoral	6	8	9,87	0,0008
	Inland	6	79		
Lesion size	≤ 2 cm	1	41	0,16	0,12
	> 2 cm	3	20		
Number of lesions	1	8	64	1,02	0,97
	>1	6	49		
Lymphangitis	absent	7	49	1,17	0,80
	present	5	41		
Adenopathy	absent	8	66	0,70	0,58
	present	4	23		
Papule	absent	11	69	6782796,24	0,99
	present	0	6		
Satellite papules	absent	10	70	0,86	0,89
	present	1	6		
Nodule	absent	9	59	0,86	0,84
	present	3	17		

Table 2 : Statistical analysis of variables tested with LRV genotypes

		LRV group		Univariate analysis	
		A	B	OR	p-value
Age	18-35 years hold	12	29	1,58	0,35
	> 35 years hold	10	38		
Gender	female	4	6	2,43	0,21
	male	12	46		
Time between two rounds of pentamidine	1 month	5	11	1,07	0,93
	> 1 month	1	7		
Time between infection and treatment	≤ 50 days	6	29	0,58	0,37
	> 50 days	8	22		
Treatment 1	cure	9	25	1,21	0,70
	failure	13	42		
Treatment 2	cure	5	11	3,33	0,31
	failure	3	9		
Suspected place of infection	Littoral	2	4	1,47	0,67
	Inland	18	47		
Lesion size	≤ 2 cm	7	23	1,12	0,88
	> 2 cm	3	11		
Number of lesions	1	12	39	0,81	0,67
	>1	10	26		
Lymphangitis	absent	10	30	1,07	0,90
	present	8	27		
Adenopathy	absent	11	44	0,42	0,13
	present	7	12		
Papule	absent	14	47	0,82	0,87
	present	1	3		
Satellite papules	absent	15	48	ND	0,99
	present	0	2		
Nodule	absent	10	41	0,44	0,21
	present	5	9		

ND : Not determined